我国专利药品平行进口研究  

Research on China’s Parallel Importation About Patented Pharmaceutical

作　　者：王瑞 WANG Rui(The Research Center of Intellectual Property,Zhongnan University of Economics and Law,Wuhan 430073)

机构地区：[1]中南财经政法大学知识产权研究中心,武汉430073

出　　处：《中国发明与专利》2020年第5期17-25,共9页China Invention & Patent

基　　金：中南财经政法大学研究生教育创新资助项目(201911504),高等学校学科创新引智计划项目(B18058)资助。

摘　　要：专利药品平行进口可以帮助平抑专利药品价格、提高医药市场可竞争性、激励药品创新和促进贸易自由化。《中华人民共和国专利法》第69条第1项确立的国际权利用尽原则为专利药品的平行进口提供了理论基础。值此医药市场转型的关键时期,实施专利药品平行进口的市场条件业已具备。中国需要做好专利药品平行进口制度与药品监管流通中质量和安全、安全进出口、市场监督等制度的衔接工作,选择合适的国家合作、建立全方位的药品追溯系统、设立单独的专利药品销售渠道以完善专利药品的平行进口制度。Establishing a parallel import system about patented pharmaceutical is of great significance for stabilizing pharmaceutical prices, increasing market competition, stimulating innovation and promoting trade liberalization. International harmonization of the exhaustion of rights doctrine, established in Article 69, Paragraph 1 of the Patent Law of the People’s Republic of China, can serve as the theoretical basis for the parallel trade system of patented pharmaceutical. The market is ready for parallel importation, during the critical period for the transformation and upgrading of the medical market. Improve the connection of parallel import system about patented pharmaceutical and drug import, drug registration, drug circulation and drug supervision. China should select appropriate countries for cooperation, establish a comprehensive drug traceability system, and establish separate patent drug sales channels to improve the construction of a parallel import system for patent drugs.

关 键 词：专利药品 平行进口 国际权利用尽 医药市场改革 

分 类 号：DF523[政治法律—民商法学] DF96[政治法律—法学]